Biotechnology
(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress
Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients...
(ACOR) Company News for October 6, 2011 – Corporate Summary
• Monsanto Co. (NYSE:MON) reported its fiscal fourth-quarter loss of $0.22 cents a share, better than the Zacks Consensus Estimate of a loss of $0.27. Revenues rose 15.1% year-over-year to $2.25...
(ENZN) Enzon Pharmaceuticals Plans a 50% Workforce Cut
Enzon Pharmaceuticals (ENZN) recently announced that it will reduce its workforce by almost half to better align its resources with much tempered pipeline activities. The research and development pipeline...
(MNTA) Momenta Pharmaceuticals and Novartis AG Sue Watson Pharmaceuticals
Momenta Pharmaceuticals, Inc. (MNTA) and Novartis AG (NVS) filed a lawsuit against Amphastar Pharmaceuticals, Inc. and Watson Pharmaceuticals...
(MRX) Medicis Pharmaceutical Sells LipoSonix Business
Medicis Pharmaceutical Corp. (MRX) recently announced to have entered into a ‘Stock Purchase Agreement’ with Solta Medical, Inc. (SLTM),...
(VPHM) ViroPharma and Halozyme Therapeutics Begin Trial
ViroPharma Inc. (VPHM) and its partner Halozyme Therapeutics (HALO) recently announced the initiation of a mid-stage trial on its drug...
(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell
We recently downgraded our rating on Enzon Pharmaceuticals Inc. (ENZN) from Neutral to Underperform with a target price of $9.50.
In mid-May 2011, Enzon announced plans to halt the development of its...
(DNDN) Dendreon Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Dendreon Corporation (DNDN) with a target price of $13 per share after appraisal of the second quarter 2011 results.
Dendreon Corporation reported weaker-than-expected...
(ACHN) Company News for September 9, 2011 – Corporate Summary
• Smithfield Foods (NYSE:SFD) posted Q1 EPS of $0.69, surpassing the Zacks Consensus Estimate of $0.68 per share. Revenues for the quarter rose 6.6% year-over-year to $3.09 billion
• PerkinElmer, Inc....
(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics...
(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation
We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $16.00.
Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical...
(GILD) Take Advantage of the Fire Sale in Healthcare
by Marc Lichtenfeld, Investment U Senior Analyst
Wednesday, August...
(ONXX) Onyx Analyst Downgrades Shares to Underperform
We recently downgraded our recommendation on Onyx Pharmaceuticals, Inc. (ONXX) to Underperform from Neutral.
We note that Onyx Pharma’s second quarter 2011 loss of 56 cents was well below expectations,...
(OPTR) Optimer Pharmaceuticals – Bull of the Day
Optimer Pharmaceuticals’ (OPTR) second quarter 2011 loss per share of $0.52 was wider than the year-ago loss, but we are encouraged by the FDA approval and subsequent launch of Dificid, an antibiotic...
(ANX) Company News for August 11, 2011 – Corporate Summary
• According to a report in The New York Times, Capital One (NYSE:COF) has decided to acquire the U.S. credit card business segment of HSBC holdings (NYSE:HSBC) ...
(MITI) Micromet Loss Less Than Analyst Estimates – Revenues Rise
Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting...
(ENZN) Enzon Pharmaceuticals’ Weak Top Line Widens Loss
Enzon Pharmaceuticals’ (ENZN) second quarter 2011 net loss of 12 cents per share (excluding restructuring charge) was wider than the loss of 8 cents suffered in the year-ago quarter as the decline in royalty...
(ACOR) Acorda Therapeutics Gains – Earnings Miss Estimates
Acorda Therapeutics Inc. (ACOR) recorded adjusted earnings of 7 cents per share for the second quarter of fiscal 2011, compared with a loss of 18 cents in the year-ago period. The Zacks Consensus Earnings...
(GILD) Gilead Sciences Earnings Grow With HIV Franchise
Gilead Sciences Inc.’s (GILD) adjusted earnings per share of 95 cents for the second quarter of 2011 were 14 cents above the year-earlier earnings of 81 cents. The earnings growth was driven by a solid...
(CTIC) Cell Therapeutics Quarterly Earnings Lag – Company Pares Loss
Cell Therapeutics (CTIC) suffered a net loss of 14 cents per share in the second quarter of 2011, compared with a net loss of 46 cents (excluding special items) per share in the year-ago quarter. The narrower...
(VPHM) ViroPharma Quarterly Earnings Report Misses Due to Higher Expenses
ViroPharma Inc. (VPHM) posted second quarter fiscal 2011 earnings of 36 cents per share, missing the Zacks Consensus Estimate by 3 cents and the year-ago figure by a penny. Despite higher revenues, earnings...
(ACOR) Company News for August 2, 2011 – Corporate Summary
• Allstate Corporation (NYSE:ALL) reported Q2 loss of $1.23, lower than the Zacks Consensus Estimate of $1.53 per share. Revenues for the quarter increased by 5% year-over-year to $8.08 billion,...
(AMGN) Company News for August 1, 2011 – Corporate Summary
• Chevron Corp. (NYSE:CVX) reported a jump in its second-quarter 2011 profits, benefiting from higher oil prices and stronger refining margins. Earnings per share (excluding adjustments for foreign-currency effects)...
(AMGN) Debt Ceiling Debate and Dismal GDP Add To Market Stress
The debt debate continues to steal the spotlight from earnings and economic reports. The stock market has lost ground in recent days due to this uncertain environment even as corporate earnings reports have broadly come ahead of expectations.
With both sides in the...
(AMGN) Amgen Beats Earnings Expectations – Updates Outlook
Amgen (AMGN) reported second quarter earnings per share of $1.35, 5 cents above the Zacks Consensus Estimate and 0.7% above the year-ago earnings. Total revenues increased 4% to $3,959 million in the second...
(AMLN) Amylin Pharmaceuticals Loss Narrows on Lower Costs
Amylin Pharmaceuticals (AMLN) reported a net loss of 21 cents per share in the second quarter of 2011, a penny wider than the Zacks Consensus Estimate but well below the year-ago loss of 28 cents. Despite...
(REGN) Regeneron Pharmaceuticals Gets Mixed Data for REGN88
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi Aventis (SNY) recently announced data from two mid-stage studies of their pipeline...
(ACOR) Acorda Therapeutics Inks Deal with Medtronic
Acorda Therapeutics, Inc. (ACOR) recently entered into a licensing agreement with Medtronic, Inc. (MDT) for AC105. The company acquired...
(MITI) Micromet Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $6.00 per share.
We believe Micromet’s lead pipeline candidate, blinatumomab, holds tremendous potential in the...
(OPTR) Optimer Pharmaceuticals Analyst Maintains Neutral
We have maintained a Neutral rating on Optimer Pharmaceuticals, Inc. (OPTR) with a target price of $12.00 per share.
We find the US Food and Drug Administration’s (FDA) approval of Optimer’s first...